GlassScriptPhysician profile
Donna Tait Diaz
NPI 1316033582
$2,132.20
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $191 · 2020: $44.86 · 2021: $233 · 2022: $535 · 2023: $774 · 2024: $355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,128.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $361.59 | 2019-2024 | Orilissa, Liletta, Lo Loestrin Fe |
| Pfizer INC. | $312.24 | 2019-2024 | |
| Aspira Women'S Health INC | $171.38 | 2022-2024 | Ova1 |
| Hologic Sales and Service, LLC | $154.50 | 2022-2023 | Myosure Tissue Removal Device, Novasure, Coolseal Generator |
| Daiichi Sankyo INC. | $139.86 | 2021-2024 | Injectafer |
| Mayne Pharma Commercial LLC | $129.12 | 2022-2024 | |
| Agile Therapeutics, INC. | $127.87 | 2021-2024 | Twirla |
| Therapeuticsmd, INC. | $123.17 | 2019-2022 | |
| Myriad Women'S Health, INC. | $104.55 | 2023 | Myrisk |
| Channel Medsystems, INC. | $87.45 | 2022 | |
| Exeltis, USA INC. | $59.73 | 2019-2024 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $44.08 | 2023 | |
| Mylan Pharmaceuticals INC. | $43.63 | 2021-2022 | |
| Visby Medical, INC. | $38.80 | 2023 | Visby Medical Sexual Health Click Test |
| Coopersurgical, INC. | $32.73 | 2019-2024 | Paragard T 380a |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $23.90 | 2024 | Intrarosa |
| Medtronic USA, INC. | $21.09 | 2019 | |
| Evofem Biosciences, INC. | $18.18 | 2021 | |
| Aesculap, INC. | $17.81 | 2019 | |
| Ibsa Pharma INC. | $16.87 | 2023 | Tirosint, Licart |
| Duchesnay USA Incorporated | $16.84 | 2019 | |
| Merck Sharp & Dohme LLC | $16.45 | 2021 | |
| Sumitomo Pharma America, INC. | $15.54 | 2023 | Gemtesa |
| Minerva Surgical, INC | $14.44 | 2021 | |
| Astellas Pharma US INC | $13.87 | 2022 | |
| Amag Pharmaceuticals, INC. | $13.81 | 2020 | |
| Avion Pharmaceuticals | $12.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.